pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development (Q38204680)

31 August 2017

title

pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development (English)

1 reference

31 August 2017

0 references

L Zhang

1

1 reference

31 August 2017

F Wu

2

1 reference

31 August 2017

S C Lee

3

1 reference

31 August 2017

H Zhao

4

1 reference

31 August 2017

L Zhang

5

1 reference

31 August 2017

language of work or name

English

0 references

publication date

14 April 2014

1 reference

Clinical Pharmacology & Therapeutics

31 August 2017

published in

1 reference

31 August 2017

volume

96

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

266-277

1 reference

The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

The effect of grapefruit juice on drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Antacid Therapy and Drug Kinetics1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Effects of antacids on the clinical pharmacokinetics of drugs. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Review article: drug interactions with agents used to treat acid-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Clinically significant drug interactions with antacids: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Enhancement of drug absorption by antacids. An unrecognised drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Drug-drug interaction profiles of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Avidity of Terramycin and Aureomycin for Metallic Cations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

Effect of age and Helicobacter pylori infection on gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

7 January 2021

Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

7 January 2021

Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

7 January 2021

Interference of Iron with the Absorption of Tetracylines in Man

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

7 January 2021

Competitive Inhibition of the Luminal Efflux by Multidrug and Toxin Extrusions, but Not Basolateral Uptake by Organic Cation Transporter 2, Is the Likely Mechanism Underlying the Pharmacokinetic Drug-Drug Interactions Caused by Cimetidine in the Kidn

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.87

7 January 2021

Identifiers

DOI

10.1038/CLPT.2014.87

1 reference

31 August 2017

1 reference